ONCOtracker is a leading innovation center for novel cancer treatment and testing with a focus on the diagnosis and treatment of multiple myeloma, other B-cell malignancies, and related disorders.
- Exclusive & clinically validated ELISA sBCMA testing services
- Myeloma patient-derived tumor cell lines for drug discovery and evaluation for in vitro and in vivo studies
- Large onsite biobank for research related to MM & other related disorders
- Founded by James R Berenson, MD, a leading multiple myeloma researcher & clinician
Our Areas of Focus
Serum BCMA Testing & Services
Novel serum B-cell marker for multiple myeloma and possibly other cancers and diseases. ONCOtracker’s sBCMA assay is used in pre-clinical, phase I and II studies investigating response to drug therapies.
Janus Kinase Inhibitors
Patent issued for combination of JAKi’s with immunomodulatory agents for anti-cancer applications.
Gamma Secretase Inhibitors
Patent pending for use-case of GSI as a treatment potentiator for BCMA-targeted therapies to treat multiple myeloma.
Precision Medicine
A transformative innovator in enabling data-driven treatment decisions to improve outcomes for cancer patients and reduce the cost of care.